This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Malaria & mRNA Vaccines: A Possible Salvation from One of the Most Relevant Infectious Diseases of the Global South
Acta Parasitologica Open Access 12 October 2023
-
Development of lipid nanoparticles and liposomes reference materials (II): cytotoxic profiles
Scientific Reports Open Access 27 October 2022
-
Malaria-Antigene in der Ära der mRNA-Impfstoffe
Monatsschrift Kinderheilkunde Open Access 14 July 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
06 September 2018
In the version of this article initially published, the company's name was given as Alnylam Therapeutics instead of Alnylam Pharmaceuticals in the first sentence and as Alynlam instead of Alnylam in the image caption. The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Alnylam launches era of RNAi drugs. Nat Biotechnol 36, 777–778 (2018). https://doi.org/10.1038/nbt0918-777
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0918-777
This article is cited by
-
Malaria & mRNA Vaccines: A Possible Salvation from One of the Most Relevant Infectious Diseases of the Global South
Acta Parasitologica (2023)
-
Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
Tissue Engineering and Regenerative Medicine (2023)
-
Development of lipid nanoparticles and liposomes reference materials (II): cytotoxic profiles
Scientific Reports (2022)
-
Malaria-Antigene in der Ära der mRNA-Impfstoffe
Monatsschrift Kinderheilkunde (2022)
-
The evolution of commercial drug delivery technologies
Nature Biomedical Engineering (2021)